<DOC>
	<DOCNO>NCT02915965</DOCNO>
	<brief_summary>The purpose study determine whether docetaxel , cisplatin , capecitabine ( DCX ) effective neoadjuvant chemotherapy esophagectomy patient loco-regional esophageal squamous cell carcinoma ( ESCC ) .</brief_summary>
	<brief_title>A Trial Neoadjuvant Chemotherapy Stage II , III Esophageal Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>1 . Histologic diagnosis squamous cell thoracic esophageal carcinoma Stage II III , potentially resectable . 2 . Patients must receive prior anticancer therapy . 3 . More 6 month expect survival . 4 . Age range 18 70 year . 5 . Absolute white blood cell count ≥4.0×109/L , neutrophil ≥1.5×109/L , platelet ≥100.0×109/L , hemoglobin ≥90g/L , normal function liver kidney . 6 . Karnofsky performance status ( KPS ) 90 . 7 . Signed informed consent document file . 1 . Patients diagnose suspected allergic docetaxol cisplatin capecitabine . 2 . Patients concomitant hemorrhagic disease . 3 . Pregnant breast feeding . 4 . Inability use gastric conduit esophagectomy prior surgery . 5 . Patients concomitant peripheral neuropathy , whose common toxicity criterion ( CTC ) status 2 even . 6 . Have prior malignancy esophageal carcinoma , carcinoma situ cervix , nonmelanoma skin cancer cure early stage prostate cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>